Sulfonamide derivatives as Bcl2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Details for Australian Patent Application No. 2010326728 (hide)

Owner Abbott Laboratories

Inventors Park, Chang H.; Bruncko, Milan; Ding, Hong; Doherty, George A.; Elmore, Steven W.; Hasvold, Lisa; Hexamer, Laura; Kunzer, Aaron; Mantei, Robert A.; McClellan, William J.; Park, CheolMin; Petros, Andrew M.; Song, Xiaohong; Souers, Andrew J.; Sullivan, Gerard M.; Tao, Zhi-Fu; Wang, Gary T.; Wang, Le; Wang, Xilu; Wendt, Michael D.; Hansen, Todd M.

Agent Spruson & Ferguson

Pub. Number AU-A-2010326728

PCT Pub. Number WO2011/068561

Priority 12/631,404 04.12.09 US

Filing date 1 June 2010

Wipo publication date 9 June 2011

International Classifications

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/404 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

C07D 209/32 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 211/96 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 213/64 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 215/20 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 217/16 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 231/56 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 235/26 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

C07D 249/04 (2006.01) Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

C07D 295/125 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 295/14 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 309/14 (2006.01) Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

31 May 2012 PCT application entered the National Phase

  PCT publication WO2011/068561 Priority application(s): WO2011/068561

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010326737-Means and methods for diagnosing multiple sclerosis

2010326727-Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases